COMPASS er en forkortelse for “Cardiovascular Outcomes for People Using Anticoagulation Strategies” og er betegnelsen for studier af lægemidlet Xarelto. COMPASS regime er betegnelsen for kombinationen af Xarelto 2,5 mg x 2 dgl. og Acetylsalicylsyre 100 mg dgl. der anvendes til forebyggelse af hjertekarsygdomme hos højrisikopatienter.
Referencer
- Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020 Jul 7;142(1):40-48. doi: 10.1161/CIRCULATIONAHA.120.046048. Epub 2020 May 21. Erratum in: Circulation. 2020 Jul 7;142(1):e23. PMID: 32436455.
- Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, Ha JW, Varigos J, Tonkin A, O’Donnell M, Bhatt DL, Fox K, Maggioni A, Berkowitz SD, Bruns NC, Yusuf S, Eikelboom JW. Stroke Outcomes in the COMPASS Trial. Circulation. 2019 Feb 26;139(9):1134-1145. doi: 10.1161/CIRCULATIONAHA.118.035864. PMID: 30667279.
Sidst opdateret 6. august 2023